Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

TLN-372 in Advanced KRAS Mutant Solid Tumors

The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors

Participants needed: 240
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Treeline Biosciences, Inc.Updated: Apr 21, 2026Locations: 11
Eligibility criteria

Patients must have measurable disease at study entry. [+3]

Patients must not have active brain metastases. [+6]

Read more
Status: Recruiting

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

Participants needed: 180
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Treeline Biosciences, Inc.Updated: Mar 27, 2026Locations: 12
Eligibility criteria

Participant must have measurable disease at study entry [+7]

Participants must not have current central nervous system (CNS) involvement. Par... [+6]

Read more
Status: Recruiting

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.

Participants needed: 50
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Treeline Biosciences, Inc.Updated: Oct 10, 2025Locations: 5
Eligibility criteria

At least 18 years of age at the time of signing the informed consent form (ICF). [+14]

Participants must not have prior systemic anti-cancer treatment less than or equ... [+4]

Read more